[O12] Oral Session 12"Gene editing and other gene transfer technologies and stem cells　　"

[O12-1] Development and supply of efficient and safe adenovirus vectors expressing highly-multiplex guide RNAs of CRISPR/Cas9: application to studies of genome-editing therapy of cancer, hepatitis, SARS-CoV-2, autophagy and genetic diseases.

^○Tomoko Nakanishi¹, Tomomi Nakahara², Kiyoshi Yamaguchi³, Yoichi Furukawa³, Takasuke Fukuhara⁴, Hiromi Chayama⁵, Kohji Moriishi^6,7, Wataru Kamitani⁸, Yoshinobu Ichimura⁹, Masaaki Komatsu⁹, Nobutaka Hattori¹, Izumu Saito¹⁰, Tohru Kiyono¹¹ (1.Juntendo Univ., Ctr. for Biomed. Res. Resources, 2.National Cancer Center Research Institute, Dept. of Immune Med., 3.Univ. of Tokyo, Inst. of Med. Sci., 4.Hokkaido Univ., Dept. of Microbiology and Immunol., 5.Hiroshima Univ., Grad. Sch. of Biomed. and Health Sci., 6.Univ. of Yamanashi, Dept. of Microbiology, 7.Hokkaido Univ., Inst. for Genetic Med., 8.Gunma Univ., Grad. Sch. of Med., 9.Juntendo Univ., Dept. of Physiol., 10.Juntendo Univ., 11.National Cancer Center Research Institute)